LU91674I2 - Cimzia-certolizumab pegol - Google Patents

Cimzia-certolizumab pegol

Info

Publication number
LU91674I2
LU91674I2 LU91674C LU91674C LU91674I2 LU 91674 I2 LU91674 I2 LU 91674I2 LU 91674 C LU91674 C LU 91674C LU 91674 C LU91674 C LU 91674C LU 91674 I2 LU91674 I2 LU 91674I2
Authority
LU
Luxembourg
Prior art keywords
cimzia
certolizumab pegol
pegol
certolizumab
Prior art date
Application number
LU91674C
Other languages
English (en)
French (fr)
Other versions
LU91674I9 (enEXAMPLES
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91674(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of LU91674I2 publication Critical patent/LU91674I2/fr
Publication of LU91674I9 publication Critical patent/LU91674I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
LU91674C 2000-06-06 2010-03-29 Cimzia-certolizumab pegol LU91674I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (2)

Publication Number Publication Date
LU91674I2 true LU91674I2 (fr) 2010-05-31
LU91674I9 LU91674I9 (enEXAMPLES) 2019-01-03

Family

ID=9893121

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91674C LU91674I2 (fr) 2000-06-06 2010-03-29 Cimzia-certolizumab pegol

Country Status (42)

Country Link
US (4) US7012135B2 (enEXAMPLES)
EP (4) EP1287140B1 (enEXAMPLES)
JP (3) JP4064812B2 (enEXAMPLES)
KR (1) KR20020047097A (enEXAMPLES)
CN (1) CN1289671C (enEXAMPLES)
AP (1) AP2092A (enEXAMPLES)
AR (1) AR033978A1 (enEXAMPLES)
AT (1) ATE451460T1 (enEXAMPLES)
AU (1) AU783756B2 (enEXAMPLES)
BE (1) BE2010C019I2 (enEXAMPLES)
BG (1) BG66072B1 (enEXAMPLES)
BR (2) BR0106682A (enEXAMPLES)
CA (2) CA2707766C (enEXAMPLES)
CY (6) CY1109889T1 (enEXAMPLES)
CZ (1) CZ300737B6 (enEXAMPLES)
DE (3) DE122010000027I1 (enEXAMPLES)
DK (4) DK1287140T3 (enEXAMPLES)
EC (1) ECSP024210A (enEXAMPLES)
ES (5) ES2337763T3 (enEXAMPLES)
FR (1) FR10C0015I2 (enEXAMPLES)
GB (2) GB0013810D0 (enEXAMPLES)
HU (4) HU230561B1 (enEXAMPLES)
IL (3) IL147992A0 (enEXAMPLES)
IS (2) IS2808B (enEXAMPLES)
LT (1) LT2308975T (enEXAMPLES)
LU (1) LU91674I2 (enEXAMPLES)
MX (1) MXPA01013440A (enEXAMPLES)
MY (1) MY136603A (enEXAMPLES)
NL (1) NL300982I9 (enEXAMPLES)
NO (4) NO334808B1 (enEXAMPLES)
NZ (1) NZ516596A (enEXAMPLES)
OA (1) OA12282A (enEXAMPLES)
PE (1) PE20020292A1 (enEXAMPLES)
PL (2) PL212738B1 (enEXAMPLES)
PT (4) PT3059314T (enEXAMPLES)
RU (1) RU2303604C2 (enEXAMPLES)
SI (3) SI1287140T1 (enEXAMPLES)
SK (1) SK288343B6 (enEXAMPLES)
TR (1) TR201900227T4 (enEXAMPLES)
TW (2) TWI316088B (enEXAMPLES)
WO (1) WO2001094585A1 (enEXAMPLES)
ZA (1) ZA200200097B (enEXAMPLES)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
AU2003225900A1 (en) * 2002-03-20 2003-10-08 Pharmacia Corporation Antibody disulfide isomers, use thereof, and methods of analyzing same
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
PT2371392E (pt) 2002-05-02 2015-10-07 Wyeth Holdings Llc Conjugados de derivado da caliqueamicina - transportador
ATE518885T1 (de) 2002-05-28 2011-08-15 Ucb Pharma Sa Peg-positionsisomer von einem antikorper gegen tnfalpha (cdp870)
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2800126A1 (en) * 2002-07-19 2004-01-29 Abbott Biotechnology Ltd. Treatment of tnf.alpha. related disorders
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
US20040247588A1 (en) * 2002-08-28 2004-12-09 Johnson Robert E. Formulations of modified antibodies and methods of making the same
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CN101899106A (zh) 2002-10-29 2010-12-01 阿纳福公司 三聚细胞因子的三聚结合蛋白
ES2347239T3 (es) 2002-12-02 2010-10-27 Amgen Fremont Inc. Anticuerpos dirigidos al factor de necrosis tumoral y usos de los mismos.
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
AU2004205684A1 (en) * 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
MXPA05008785A (es) * 2003-02-19 2005-10-18 Pharmacia Corp Esteres de polietilen glicol activados.
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
AU2004220325B2 (en) * 2003-06-30 2011-05-12 Domantis Limited Polypeptides
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
ES2391457T3 (es) * 2003-08-13 2012-11-26 Sandoz Ag Procedimiento para la purificación de polipéptidos recombinantes
ES2281822T3 (es) * 2003-08-13 2007-10-01 Sandoz Ag Vectores de expresion, celulas huesped transformadas y procedimiento de fermentacion para la produccion de polipeptidos recombinantes.
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
US8022040B2 (en) * 2004-11-29 2011-09-20 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
DE602005026571D1 (de) * 2004-12-29 2011-04-07 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
WO2006125229A2 (en) 2005-05-16 2006-11-23 Abbott Biotechnology Ltd. Use of tnf inhibitor for treatment of erosive polyarthritis
US7964707B2 (en) * 2005-06-01 2011-06-21 Micromet Ag Anti-IL2 antibodies
KR101539545B1 (ko) 2005-06-07 2015-07-24 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
GB0520169D0 (en) * 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
EP2004231A4 (en) 2006-04-07 2013-07-10 Nektar Therapeutics CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
WO2008063213A2 (en) * 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
AU2007269714A1 (en) 2006-07-03 2008-01-10 Charles David Adair Composition for modulating the expression of cell adhesion molecules
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN101652128B (zh) * 2007-03-02 2012-12-19 法纳姆公司 使用蜡状材料的缓释组合物
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド 質量を削減した長時間作用剤形
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
WO2009026274A1 (en) * 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
AU2009212079B2 (en) * 2008-02-05 2012-08-30 Delenex Therapeutics Ag Antigen-binding polypeptides against cartilage degeneration
CA2722622C (en) * 2008-05-07 2018-01-02 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
DK2752428T3 (da) 2008-06-25 2020-02-24 Novartis Ag Humanisering af kanin-antistoffer under anvendelse af et universelt antistof-framework
EP3964526A1 (en) 2008-06-25 2022-03-09 Novartis AG Humanization of rabbit antibodies using a universal antibody framework
US8673310B2 (en) * 2008-06-25 2014-03-18 ESBA Tech, an Alcon Biomedical Research Unit LLC Stable and soluble antibodies inhibiting TNFα
PL3722310T3 (pl) 2008-06-25 2025-01-20 Novartis Ag Stabilne i rozpuszczalne przeciwciała hamujące vegf
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
TW201031421A (en) * 2009-01-29 2010-09-01 Abbott Lab IL-1 binding proteins
WO2011003622A1 (en) 2009-07-10 2011-01-13 Ablynx N.V. Method for the production of variable domains
JP6132551B2 (ja) 2009-09-24 2017-05-24 ユセベ ファルマ ソシエテ アノニム シャペロン活性を保持するプロテアーゼ欠損ＤｅｇＰ並びにノックアウトＴｓｐ及びｐｔｒ遺伝子を持つ、組換えタンパク質発現のための細菌株
NZ623607A (en) 2009-10-23 2016-07-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc MONOCLONAL ANTIBODIES DIRECTED AGAINST CD52
PE20130528A1 (es) 2010-04-07 2013-05-26 Abbvie Inc PROTEINAS QUE SE UNEN AL TNF-alfa
GB201012599D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
KR102066292B1 (ko) 2011-06-01 2020-01-14 인트랙슨 액토바이오틱스 엔.브이. 박테리아용 폴리시스트론 발현 시스템
PT2731973T (pt) 2011-07-13 2018-02-22 Ucb Biopharma Sprl Estirpe hospedeira bacteriana que expressa dsbc recombinante
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
CN103917639B (zh) 2011-09-23 2017-09-26 英特瑞克斯顿阿克图比奥帝克斯有限公司 经修饰的革兰氏阳性细菌及其用途
EP2758512B1 (en) 2011-09-23 2018-05-09 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
KR20200143502A (ko) 2012-08-13 2020-12-23 제넨테크, 인크. 항-jagged 항체 및 사용 방법
EP3134439B1 (en) 2014-04-21 2018-12-26 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
BR112017013398B1 (pt) 2014-12-22 2023-12-05 Ucb Biopharma Sprl Método de fabricar anticorpo ou fragmento de ligação ao antígeno do mesmo
WO2017035430A2 (en) * 2015-08-27 2017-03-02 Kolltan Pharmaceuticals, Inc. Anti-alk antibodies and methods for use thereof
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
US10905727B2 (en) 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
CR20180594A (es) * 2016-06-02 2019-07-29 Abbvie Inc Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
SI3658192T1 (sl) 2017-12-01 2021-08-31 Abbvie Inc. Agonist glukokortikoidnega receptorja in njegovi imunokonjugati
MA54857A (fr) 2019-01-31 2021-12-08 Numab Therapeutics AG Anticorps multispécifiques ayant une spécificité pour tnfa et il-17a, anticorps ciblant il-17a, et leurs procédés d'utilisation
KR102323342B1 (ko) 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating tgf-b signaling
WO2023025248A1 (zh) 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
MX2024003696A (es) 2021-09-24 2024-05-29 Xbrane Biopharma Ab Construcciones de adn y celulas huespedes para expresar proteinas recombinantes.
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
US5733742A (en) * 1993-06-03 1998-03-31 Therapeutic Antibodies Inc. Production of antibody fragments from whole blood
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
DE122004000003I2 (de) 1996-02-09 2007-03-29 Abbott Biotech Ltd Humane Antikörper welche an humanen TNFalpha Binden
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
AU9262598A (en) * 1997-08-18 1999-03-08 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
DE69939033D1 (de) 1998-03-12 2008-08-14 Nektar Therapeutics Al Corp Verfahren zur Herstellung von Polymerkonjugaten
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
US20080269465A1 (en) 2008-10-30
JP4476989B2 (ja) 2010-06-09
US7186820B2 (en) 2007-03-06
US7012135B2 (en) 2006-03-14
CY1114143T1 (el) 2016-07-27
BE2010C019I2 (enEXAMPLES) 2020-08-20
CY1118220T1 (el) 2017-06-28
HU230561B1 (hu) 2016-12-28
ATE451460T1 (de) 2009-12-15
CA2707766C (en) 2013-05-21
IS6217A (is) 2002-01-03
NO339282B1 (no) 2016-11-21
SK288343B6 (sk) 2016-04-01
SI1287140T1 (sl) 2010-04-30
NO20160694A1 (no) 2002-04-08
AR033978A1 (es) 2004-01-21
AP2092A (en) 2010-02-28
ES2337763T3 (es) 2010-04-29
CN1383450A (zh) 2002-12-04
BR0106682A (pt) 2002-05-14
IL147992A0 (en) 2002-09-12
EP2230308B1 (en) 2013-01-23
NO334808B1 (no) 2014-06-02
DE122010000027I1 (de) 2010-08-12
PE20020292A1 (es) 2002-05-08
JP5185143B2 (ja) 2013-04-17
ES2707714T3 (es) 2019-04-04
EP1287140B1 (en) 2009-12-09
ES2230975B2 (es) 2007-04-16
PL212738B1 (pl) 2012-11-30
NO20020554D0 (no) 2002-02-04
DE60140738D1 (de) 2010-01-21
US7402662B2 (en) 2008-07-22
CZ300737B6 (cs) 2009-07-29
PT3059314T (pt) 2019-02-01
MXPA01013440A (es) 2003-09-04
DK3059314T3 (en) 2019-02-18
BG106278A (bg) 2002-12-29
EP3059314A1 (en) 2016-08-24
JP2003535591A (ja) 2003-12-02
NO20020554L (no) 2002-04-08
EP2230308A1 (en) 2010-09-22
JP4064812B2 (ja) 2008-03-19
CY2019018I2 (el) 2020-05-29
PL353960A1 (en) 2003-12-15
HK1148776A1 (en) 2011-09-16
GB2366800A (en) 2002-03-20
SK3152002A3 (en) 2002-07-02
EP3059314B1 (en) 2018-10-24
ES2403217T3 (es) 2013-05-16
DK2308975T3 (da) 2016-10-31
HUP1600016A2 (en) 2002-10-28
CY2019018I1 (el) 2020-05-29
US7977464B2 (en) 2011-07-12
NO341218B1 (no) 2017-09-11
CY1121173T1 (el) 2020-05-29
LT2308975T (lt) 2016-11-10
DE10192353T1 (de) 2003-05-22
KR20020047097A (ko) 2002-06-21
IL147992A (en) 2009-06-15
HU230553B1 (hu) 2016-11-28
CY2010011I2 (el) 2012-01-25
FR10C0015I2 (fr) 2011-12-30
US20020151682A1 (en) 2002-10-17
RU2303604C2 (ru) 2007-07-27
DK2230308T3 (da) 2013-05-06
MY136603A (en) 2008-10-31
HK1051385A1 (en) 2003-08-01
NL300982I9 (nl) 2019-05-06
NZ516596A (en) 2004-07-30
PL218516B1 (pl) 2014-12-31
NO2014026I2 (no) 2018-02-14
US20060233800A1 (en) 2006-10-19
BG66072B1 (bg) 2011-01-31
GB0013810D0 (en) 2000-07-26
NO2014026I1 (no) 2014-10-23
EP2308975A1 (en) 2011-04-13
CZ2002837A3 (cs) 2002-05-15
GB2366800B (en) 2005-01-19
DK1287140T3 (da) 2010-04-19
ES2230975A1 (es) 2005-05-01
TWI353358B (en) 2011-12-01
AU6051101A (en) 2001-12-17
PT1287140E (pt) 2010-03-08
LU91674I9 (enEXAMPLES) 2019-01-03
AP2002002690A0 (en) 2002-12-31
EP2308975B1 (en) 2016-08-10
PT2308975T (pt) 2016-11-14
PL399351A1 (pl) 2012-12-17
CA2380298C (en) 2010-09-28
BRPI0106682B8 (pt) 2021-05-25
CY2010011I1 (el) 2012-01-25
OA12282A (en) 2006-05-11
CY1109889T1 (el) 2012-01-25
GB0128386D0 (en) 2002-01-16
HUP1600483A2 (enEXAMPLES) 2002-10-28
EP1287140A1 (en) 2003-03-05
FR10C0015I1 (enEXAMPLES) 2010-04-16
CN1289671C (zh) 2006-12-13
TR201900227T4 (tr) 2019-02-21
TW200817430A (en) 2008-04-16
ES2600080T3 (es) 2017-02-07
IS3016B (is) 2019-10-15
ZA200200097B (en) 2003-01-06
HUP0202346A3 (en) 2004-11-29
HUP0202346A2 (en) 2002-10-28
CA2707766A1 (en) 2001-12-13
HUS1700013I1 (hu) 2017-08-28
CA2380298A1 (en) 2001-12-13
JP2007105043A (ja) 2007-04-26
NO20131316L (no) 2002-04-08
WO2001094585A1 (en) 2001-12-13
IL195085A0 (en) 2009-08-03
NL300982I1 (enEXAMPLES) 2019-05-01
AU783756B2 (en) 2005-12-01
SI2308975T1 (sl) 2016-11-30
BRPI0106682B1 (pt) 2020-10-13
HU230669B1 (hu) 2017-07-28
JP2009171966A (ja) 2009-08-06
TWI316088B (en) 2009-10-21
PT2230308E (pt) 2013-05-03
ECSP024210A (es) 2002-05-23
IS2808B (is) 2012-09-15
SI2230308T1 (sl) 2013-06-28
US20030026805A1 (en) 2003-02-06

Similar Documents

Publication Publication Date Title
NL300982I9 (nl) Certolizumab
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
DE60135536D1 (de) tungsfunktion
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DE60128645D1 (de) Rotor-Schaufelblatt-Zusammenbau
DE50104056D1 (de) Gewichtsmanschette
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
DE50104651D1 (de) Fahrzeugfaltverdeck
DE10192638T1 (de) Bohrstangenladevorrichtung
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
DE50007634D1 (de) Kardioplegieballonkatheter
DE10052925B4 (de) Schaukelbett
ATE476423T1 (de) Benzoylpyridazine
DE10195909T1 (de) Viehfüttervorrichtung
FI20000577A0 (fi) Pyridatsinyylifenyylihydratsoneja
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
DE10195992T1 (de) Oberflächenendbearbeitungsbelag
ATE284887T1 (de) Thienopyrrolidinone
DE60109374D1 (de) Schnellbaukarosseriestruktur